An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
The ATS/IDSA Statement outlines recommended treatments for various NTM species. Though these recommendations are based on all available knowledge and expertise, every patient is different, and so your doctor may decide to change your regimen based on how you respond to treatment. These treatment variations are also discussed in some detail in the Statement.
A comprehensive revision to the Statement is currently underway. It is anticipated that the revised Statement will be published sometime in 2018.
David E. Griffith, Timothy Aksamit, Barbara A. Brown-Elliott, Antonino Catanzaro, Charles Daley, Fred Gordin, Steven M. Holland, Robert Horsburgh, Gwen Huitt, Michael F. Iademarco, Michael Iseman, Kenneth Olivier,Stephen Ruoss, C. Fordham von Reyn, Richard J. Wallace, Jr., and Kevin Winthrop, on behalf of the ATS Mycobacterial Diseases Subcommittee